John Abraham starrer Parmanu – The Story Of Pokhran has been recieved very well at the box office. The movie showed almost 60% growth on its second day collecting 7.64 crores. It opened with an ordinary amount of 4.82 crores. 12.46 crores is what it collected in 2 days but it has surprised further on day 3.
The movie opened to a strong advance on Sunday as word of mouth did its magic by then. Parmanu – The Story Of Pokhran has received some raving reviews by the critics and also audience has been loving this. It was expected to grow on the weekend and without disappointing the movie did the same.
As per the early trends flowing in, the movie movie could just about touch the double digits on its day 3 at the box office. It can collect in the range of 8-10 crores. This is huge for a film which without any strong promotions released amidst the finale period of IPL. The number would’ve been higher but the final of IPL affected its proceedings in the evening shows.
If we go by the early trends, the movie could have its 1st weekend in the range of 20-22 crores. Also, this has every chance of trending superbly since Monday given the healthy word of mouth. Also, IPL has been concluded now and this will act as an added advantage for the film.
“Nothing could make me happier today than the validation of our efforts to celebrate our unsung heroes by our audience across India! I have been getting so many calls from our distributors and exhibitors and I’m thankful to each one of them for their unstinted support and for standing by and loving this labour of love,” John Abraham, who is playing the lead role in the film apart from producing it, said in a statement.
He added that he is humbled and grateful to each one of them.
The film is based on the series of nuclear test explosions which took place in Pokhran in 1998
Parmanu – The Story Of Pokhran also stars Diana Penty and Boman Irani. The film is jointly produced by JA Entertainment, Zee Studios and Kyta Productions. Vashu Bhagnani’s Pooja Entertainment is its All India Distributor.